Especially in the treatment of patients with hormone receptor (HR)-positive and ERBB2 (formerly HER2)-negative advanced breast cancer, CDK4 and CDK6 inhibitors (abemaciclib, ribociclib, and palbociclib) have an important role [15–19]. This evidence concerns the gene CDK4 and breast carcinoma.